ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Impact of Donor Race on Tacrolimus Dose Requirement for Liver Transplant Recipients

N. Nesselhauf1, S. January1, J. Hagopian1, K. Progar1, A. Khan2

1Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, 2Surgery, Washington University School of Medicine, St. Louis, MO

Meeting: 2020 American Transplant Congress

Abstract number: B-135

Keywords: African-American, Dosage, Gene polymorphism, Immunosuppression

Session Information

Session Name: Poster Session B: Liver: Immunosuppression and Rejection

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: It is well described that there is interpatient variability in tacrolimus dose requirements among transplant recipients. CYP3A5 plays a role in this variability. Black donors are more likely to be CYP3A5 *1 expressers compared to Caucasians. Due to this difference, this study aims to compare tacrolimus dosing requirements of tacrolimus-IR (tac-IR) and tacrolimus-XR (LCPT) in Caucasian liver transplant (OLT) recipients receiving a liver from Black or Caucasian donors.

*Methods: This single-center retrospective analysis included patients that received an OLT who were transitioned from tac-IR to LCPT and remained on LCPT for at least 3 months. A matched control group of patients on tac-IR were also compared. Patients were divided into groups based on donor race and tacrolimus formulation. The primary endpoint was defined as total daily weight adjusted tacrolimus dose (mg/kg)/(ng/mL) calculated at 3 and 6 months post-transplant. Composite of graft loss, death and biopsy-proven rejection (BPAR) were compared by donor race for tac-IR and LCPT at 1 year post-OLT. Differences in the primary and composite endpoints were evaluated via Chi-square analysis and independent samples t-test where appropriate.

*Results: There were 90 patients who received a Caucasian donor liver and 19 patients that received a Black donor liver. There was no difference in recipient demographic variables of age, sex, BMI and MELD score at the time of OLT. There was no difference in Tac-IR weight adjusted dose requirements (mg/kg)/(ng/mL) between Caucasian and Black donors at 3 months (p=0.33) and 6 months post-OLT (p=0.18). There was no difference incidence of BPAR between the two donor group for Tac-IR (7% vs. 1%, p=0.47). Similar results for the LCPT group, with no difference in LCPT weight adjusted dose requirements between Caucasian and Black donors at 3 months (p=0.36) and 6 months post-OLT (p=0.27). Incidence of BPAR between the two donor groups (11% vs. 3%, p=0.27) we not different.

*Conclusions: In the early post-transplant period, there is no difference in tacrolimus dose requirements in Caucasian OLT recipients based on donor race.

Tac-IR Group
Caucasian Donor (n=42) Black Donor (n=12) P-value
Tac-IR at 3 month (mg/kg) /(ng/mL) 0.017 ± 0.012 0.021 ± 0.013 0.33
Tac-IR at 6 month (mg/kg)/(ng/mL) 0.014 ± 0.009 0.018 ± 0.012 0.18
1 year composite (n, %) 7 (16.7) 1 (8.3) 0.47
LCPT Group
Caucasian Donor (n=47) Black Donor (n=7) P-value
LCPT at 3 month (mg/kg) /(ng/mL) 0.011 ± 0.011 0.013 ± 0.004 0.75
LCPT at 6 month (mg/kg) /(ng/mL) 0.014 ± 0.014 0.021 ± 0.020 0.36
1 year composite (n, %) 11 (23.4) 3 (42.8) 0.27
  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Nesselhauf N, January S, Hagopian J, Progar K, Khan A. Impact of Donor Race on Tacrolimus Dose Requirement for Liver Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/impact-of-donor-race-on-tacrolimus-dose-requirement-for-liver-transplant-recipients/. Accessed May 9, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences